Fundraising FoxSR One Capital Management — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Board seatKatarina Pance· per SEC Form D
Co-investorsLongitude CapitalConnecticut InnovationsLifeSci Venture PartnersOUP (Osage University Partners)abrdn plcInvus
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)inLawrence Kong(Executive Officer)inRon Park(President & CEO)inFrancine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in
BoardJayson Punwani(Director)in
Board seatLaetitia SchwabMatthew R. Patterson· per SEC Form D
Co-investorsBEVCPivotal Life SciencesAbingworth
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardCarl Gordon(Director)inValerie Odegard(Director)
Board seatJill Carroll· per SEC Form D
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+9 more
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMed+6 more
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM Healthcare InvestmentsHBM PartnersLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture Capital+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.